 |
Flovent Rotadisk Dosage
Generic name: fluticasone propionate
Dosage form: powder, metered
See also:
This dosage information does not include all the information needed to use Flovent Rotadisk safely and effectively. See full prescribing information for Flovent Rotadisk.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
FLOVENT DISKUS should be administered by the orally inhaled route only in patients 4 years and older. Individual patients will experience a variable time to onset and degree of symptom relief. Maximum benefit may not be achieved for 1 to 2 weeks or longer after starting treatment.
After asthma stability has been achieved, it is always desirable to titrate to the lowest effective dosage to reduce the possibility of side effects. For patients who do not respond adequately to the starting dosage after 2 weeks of therapy, higher dosages may provide additional asthma control. The safety and efficacy of FLOVENT DISKUS when administered in excess of recommended dosages have not been established.
The recommended starting dosage and the highest recommended dosage of FLOVENT DISKUS, based on prior asthma therapy, are listed in Table 1.
Table 1. Recommended Dosages of FLOVENT DISKUS
| NOTE: In all patients, it is desirable to titrate to the lowest effective dosage once asthma stability is achieved. | ||
| Previous Therapy | Recommended Starting Dosage | Highest Recommended Dosage |
| Adult and adolescent patients (aged ≥12 years) | ||
| Bronchodilators alone | 100 mcg twice daily | 500 mcg twice daily |
| Inhaled corticosteroids | 100-250 mcg twice dailya | 500 mcg twice daily |
| Oral corticosteroidsb | 500-1,000 mcg twice dailyc | 1,000 mcg twice daily |
| Pediatric patients (aged 4-11 years)d | 50 mcg twice dailya | 100 mcg twice daily |
aStarting dosages above 100 mcg twice daily for adult and adolescent patients and 50 mcg twice daily for pediatric patients aged 4 to 11 years may be considered for patients with poorer asthma control or those who have previously required doses of inhaled corticosteroids that are in the higher range for the specific agent.
bFor patients currently receiving chronic oral corticosteroid therapy, prednisone should be reduced no faster than 2.5 to 5 mg/day on a weekly basis beginning after at least 1 week of therapy with FLOVENT DISKUS. Patients should be carefully monitored for signs of asthma instability, including serial objective measures of airflow, and for signs of adrenal insufficiency [see Warnings and Precautions (5.4)]. Once prednisone reduction is complete, the dosage of FLOVENT DISKUS should be reduced to the lowest effective dosage.
cThe choice of starting dosage should be made on the basis of individual patient assessment. A controlled clinical study of 111 oral corticosteroid-dependent patients with asthma showed few significant differences between the 2 doses of FLOVENT DISKUS on safety and efficacy endpoints. However, inability to decrease the dose of oral corticosteroids further during corticosteroid reduction may be indicative of the need to increase the dose of fluticasone propionate up to the maximum of 1,000 mcg twice daily.
dBecause individual responses may vary, pediatric patients previously maintained on other inhaled corticosteroids may require dosage adjustments upon transfer to FLOVENT DISKUS.
